# US 2026/0085066 A1 · Leucine rich repeat kinase 2 (lrrk2) degrading compounds and associated methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085066 A1
- Document ID: US20260085066A1
- Status: Published application
- Kind: A1
- Application number: 19/109,277
- Filed: 2023-09-06
- Published: 2026-03-26
- Earliest claimed: 2022-09-07
- Assignees: Arvinas Operations, Inc.
- Applicants: Arvinas Operations, Inc.
- Inventors: Steven M. Sparks; Handing Dong; Michael Berlin
- Web page: https://patentgrep.com/patent/US20260085066A1

## CPC

- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 413/14: containing three or more hetero rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 471/10: Spiro-condensed systems
- A61P 25/16: Anti-Parkinson drugs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to bifunctional compounds that cause the degradation of LRRK2; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with LRRK2, including Parkinson's Disease.

## Claims

### Claim 1

A compound selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1, 2, 3)

A pharmaceutical composition comprising a compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the pharmaceutical composition further comprises additional bioactive agent.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the additional bioactive agent is an anti-inflammatory, a chemotherapy agent, or an immunomodulatory agent.

### Claim 7 (depends on 1, 2, 3, 4)

A method of treating a disease, a disorder, or a symptom causally related to LRRK2 in a subject in need thereof comprising administering to the subject an effective amount of a compound of any one of claims 1-3, or the pharmaceutical composition of claim 4.

### Claim 8 (depends on 7)

The method of claim 7, wherein the disease or disorder is Parkinson's disease (PD), LRRK2 mutation associated PD, primary tauopathies, lewy body dementia, Crohn's Disease, Leprosy, neuroinflammation, Progressive Supranuclear Palsy, Picks disease, FTDtau, TDP-43 Frontal Temporal Dementia, TDP-43 ALS, c9orf ALS, Huntington's disease, spinocerebellar ataxias (SCAs) 1, 2, 3, 6, 7 and 17, dentatorubral pallidoluysian atrophy (DRPLA), systemic lupus erythematosus (SLE), or Kennedy's disease.

### Claim 9 (depends on 7, 8)

The method of claim 7 or 8, wherein the disease or disorder is Parkinson's disease (PD), LRRK2 mutation associated PD, primary tauopathies, lewy body dementia, Crohn's Disease, Leprosy, neuroinflammation, Progressive Supranuclear Palsy, Picks disease, FTDtau, TDP-43 Frontal Temporal Dementia, TDP-43 ALS, c9orf ALS, Huntington's disease, spinocerebellar ataxias (SCAs) 1, 2, 3, 6, 7 and 17, dentatorubral pallidoluysian atrophy (DRPLA), or Kennedy's disease.

### Claim 10 (depends on 1, 2, 3, 4)

A method of treating Parkinson's disease comprising administering to a subject an effective amount of a compound of any one of claims 1-3, or the pharmaceutical composition of claim 4.

### Claim 11 (depends on 10)

The method of claim 10, wherein the Parkinson's disease is LRRK2 mutation associated Parkinson's disease.
